The EBMT is proud to announce that its Registry has achieved a landmark milestone of 10,000 chimeric antigen receptor T-cell (CAR-T) therapy patients. This significant achievement underscores the growing impact and advancement of CAR-T therapy in the treatment of haematological malignancies. Read our full story HERE.
By Prof Ibrahim Yakoub-Agha, Head of Cellular therapy Unit, Lille University Hospital, France. CIC277
Chimeric Antigen Receptor T-cell (CAR-T) therapy, a groundbreaking treatment, has quickly become a standard of care for several B-cell malignancies. Its application is now expanding into earlier lines of therapy and being explored for a broader range of diseases, including autoimmune and neuroinflammatory conditions.
The EBMT has been instrumental in patient management by establishing pioneering guidelines for managing CAR-T patients, covering all stages from initial identification to long-term follow-up. These guidelines, first published in 20201 and updated in 20212, have set the standard for clinical practice. Furthermore, the EBMT has contributed to the identification of post-CAR-T haematological toxicities, offering practical recommendations in a publication from September 20233.
With over 10,000 patients' data already captured in the EBMT Registry, the organisation is well-positioned to enhance patient outcomes and guide physicians through the complexities of CAR-T therapy. This emphasises the crucial role of consistent patient data reporting to the EBMT Registry. Generating high-quality, real-world data on CAR-T-treated patients is vital for all stakeholders to deepen their understanding of the effectiveness and safety of these therapies, ultimately improving patient outcomes. Data reporting is a cornerstone of quality care.
At Lille University Hospital, we launched our CAR-T therapy program in 2018, starting with just six patients. Since then, our activity has grown steadily, and we have now infused over 350 patients. Through this experience, we have developed a solid understanding of CAR-T efficacy across various diseases. However, our learning curve for managing toxicity is ongoing as we continue to learn about post-CAR-T complications, particularly those related to medium- and long-term toxicities.
From the beginning, reporting to the EBMT Registry was a natural decision for us. We recognise the critical role of such a professional, multinational registry in helping us explore all aspects of these complex therapies. Our ultimate goal is to provide the best possible care for our patients, and the research and studies we can conduct using the EBMT Registry will play a significant role in achieving successful outcomes.
References: